Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating restated by analysts at Credit Suisse Group in a report issued on Friday. They presently have a $96.00 target price on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 22.73% from the stock’s previous close.
Other analysts have also issued reports about the stock. Morgan Stanley reiterated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Stifel Nicolaus restated a “buy” rating and set a $56.00 target price (up from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. Chardan Capital set a $95.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Finally, BMO Capital Markets initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, April 17th. They set an “outperform” rating and a $73.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $81.74.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 78.22 on Friday. The company’s market capitalization is $7.18 billion. The stock’s 50 day moving average is $80.94 and its 200-day moving average is $61.92. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $86.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same quarter in the prior year, the firm earned ($1.05) earnings per share. The business’s revenue was up 82.9% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals will post ($5.23) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Credit Suisse Group” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2017/08/13/alnylam-pharmaceuticals-inc-alny-given-buy-rating-at-credit-suisse-group.html.
In other news, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total value of $825,000.00. Following the transaction, the executive vice president now owns 21,297 shares of the company’s stock, valued at $1,597,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the transaction, the vice president now directly owns 5,625 shares in the company, valued at approximately $393,750. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock worth $4,325,000 in the last three months. Insiders own 4.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares during the period. Wellington Management Group LLP increased its position in Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares during the period. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the period. BlackRock Inc. increased its position in Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after buying an additional 441,957 shares during the period. Finally, Baillie Gifford & Co. increased its position in Alnylam Pharmaceuticals by 2.9% in the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after buying an additional 96,805 shares during the period. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.